Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Urinary frequency

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    422 result(s) found for: Urinary frequency. Displaying page 7 of 22.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2010-018254-12 Sponsor Protocol Number: A0221090 Start Date*: 2010-03-16
    Sponsor Name:Pfizer, Inc
    Full Title: A LOCAL, MULTICENTRE, OPEN-LABEL, EXTENSION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE FLEXIBLE DOSE REGIMEN IN ELDERLY PATIENTS WITH OVERACTIVE BLADDER
    Medical condition: Treatment of overactive bladder with symptoms of frequency, urgency, and urgency incontinence (Some patients will also have urgency urinary incontinence (UUI)).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004138-12 Sponsor Protocol Number: 6294-CL-0101 Start Date*: 2017-09-26
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment o...
    Medical condition: Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10071166 Bladder pain syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) GB (Completed) BE (Completed) PL (Completed) NL (Completed) LV (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-024271-10 Sponsor Protocol Number: V00162GL203 Start Date*: 2011-07-06
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Urodynamic effect of one single vaginal application of 2 mL of V0162 gel (0.8%) in post-menopausal women with overactive bladder
    Medical condition: Overactive Bladder symptoms.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004321-15 Sponsor Protocol Number: H6D-MC-LVHK(b) Start Date*: 2007-12-14
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign P...
    Medical condition: Effects on urodynamic parameters in men with benign prostatic hyperplasia (also referred to as BPH-LUTS [lower urinary tract symptoms]) with and without urodynamic evidence of bladder outlet obstru...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011843-38 Sponsor Protocol Number: STEG-CORP_111804 Start Date*: 2009-12-07
    Sponsor Name:Grachtenhaus-Apotheke, Inh. Klaus Stegemann e.K.
    Full Title: Documentation of the efficacy and tolerability of intravesically applied oxybutynin solution in adult patients with detrusor hyperactivity caused by neurological disorder
    Medical condition: Detrusor hyperactivity caused by neurological dysfunction
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10061011 Bladder disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000840-32 Sponsor Protocol Number: CUEBS_2016 Start Date*: 2016-06-24
    Sponsor Name:FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
    Full Title: Clinical and Urodynamic Evaluation of Bladder dysfunction in multiple sclerosis patients treated with Sativex
    Medical condition: Multiple Sclerosis patients treated with nabiximols (Sativex¿, Almirall)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006070-22 Sponsor Protocol Number: A0221007 Start Date*: 2007-03-16
    Sponsor Name:Pfizer Inc
    Full Title: A 12-WEEK, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTS OF FESOTERODINE ON TREATMENT SATISFACTION AND SYMPTOM RELIEF IN OVERACTIVE BLADDER PATIENTS
    Medical condition: Overactive bladder (OAB) is a symptom complex defined by the International Continence Society (ICS) as the symptoms of urgency, with or without urgency incontinence, usually with frequency and noct...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) CZ (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003949-28 Sponsor Protocol Number: Inco_Ona1 Start Date*: 2018-08-07
    Sponsor Name:PROF. ANTONELLA GIANNANTONI - CLINICA UROLOGICA - UNIVERSITà DI PERUGIA
    Full Title: Incobotulinumtoxin versus Onabotulinumtoxin in the treatment of patients with overactive bladder syndrome
    Medical condition: neurogenic overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10032081 Other functional disorder of bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021137-32 Sponsor Protocol Number: CSAF312A2202 Start Date*: 2011-03-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, double-blind, randomized, placebocontrolled, cross-over study to evaluate the efficacy, safety and tolerability of SAF312 in subjects with neurogenic detrusor overactivity due to sp...
    Medical condition: Neurogenic detrusor overactivity due to spinal cord injury
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10020853 Hypertonic bladder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005713-37 Sponsor Protocol Number: 178-EC-001 Start Date*: 2012-04-05
    Sponsor Name:Astellas Pharma Europe Ltd
    Full Title: A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects with Overactive Bladder (OAB) Treated with Antim...
    Medical condition: Overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FI (Completed) CZ (Completed) SE (Completed) DE (Completed) ES (Completed) GB (Completed) SK (Completed) AT (Completed) BE (Completed) NO (Completed) GR (Completed) HU (Completed) DK (Completed) LV (Completed) NL (Completed) PT (Completed) PL (Completed) LT (Completed) SI (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001211-37 Sponsor Protocol Number: 905-CL-055 Start Date*: 2009-07-16
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A randomized, double-blind, parallel group, placebo controlled, multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and ...
    Medical condition: Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) FR (Completed) SK (Completed) AT (Completed) BE (Completed) IT (Completed) DE (Completed) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001452-39 Sponsor Protocol Number: 178-CL-049 Start Date*: 2008-06-05
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Randomized, Double-Blind, Parallel Group, Active Controlled, Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Sy...
    Medical condition: Symptoms of overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed) IS (Completed) CZ (Completed) LV (Completed) IE (Completed) GB (Completed) BE (Completed) FR (Completed) ES (Completed) DK (Completed) LT (Completed) SK (Completed) PT (Completed) NL (Completed) IT (Completed) HU (Completed) AT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-001116-31 Sponsor Protocol Number: ESCLIN-002/04 Start Date*: 2004-11-03
    Sponsor Name:Laboratorios Dr. Esteve S.A.
    Full Title: Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (...
    Medical condition: Urge Urinary Incontinence
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005722-21 Sponsor Protocol Number: D4280C00004 Start Date*: 2012-06-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly C...
    Medical condition: Complicated Urinary Tract Infections (cUTIs)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) DE (Completed) CZ (Completed) ES (Completed) IT (Completed) BG (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001980-19 Sponsor Protocol Number: 42756493BLC2002 Start Date*: 2018-04-25
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Surgically...
    Medical condition: Metastatic or Surgically Unresectable Urothelial Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) GB (GB - no longer in EU/EEA) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006935-38 Sponsor Protocol Number: A0221008 Start Date*: 2007-04-16
    Sponsor Name:Pfizer Inc. NYO-685-21-14,685 3rd Avenue, NEW YORK, NY 10017. US
    Full Title: 12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENT...
    Medical condition: Treatment of overactive bladder with symptoms of frequency, urgency, and urgency incontinence.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) BE (Completed) HU (Completed) DK (Completed) CZ (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001451-19 Sponsor Protocol Number: 178-CL-046 Start Date*: 2008-06-05
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with ...
    Medical condition: Symptoms of Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed) IS (Completed) CZ (Completed) LV (Completed) IE (Completed) GB (Completed) BE (Completed) FR (Completed) ES (Completed) HU (Completed) DK (Completed) LT (Completed) PT (Completed) IT (Completed) NL (Completed) AT (Completed) GR (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-001346-17 Sponsor Protocol Number: ALN-GO1-005 Start Date*: 2020-02-20
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1)
    Medical condition: Primary Hyperoxaluria Type 1 (PH1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Completed) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Ongoing) Outside EU/EEA IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006872-39 Sponsor Protocol Number: DIMS4 Start Date*: 2008-01-04
    Sponsor Name:Daval International Limited
    Full Title: A randomised, double-blind, placebo controlled study of AIMSPRO in Multiple Sclerosis
    Medical condition: Overactive Bladder in Secondary Progressive Multiple Sclerosis and the other neurological symptoms associated with Secondary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063400 Secondary progressive multiple sclerosis LLT
    9.1 10059617 Overactive bladder LLT
    9.1 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013334-24 Sponsor Protocol Number: KN0203Y-001 Start Date*: 2010-01-08
    Sponsor Name:KeyNeurotek Pharma GmbH
    Full Title: Double-blind placebo-controlled proof of concept study with the µ-receptor agonist KN203 in patients with overactive bladder syndrome Double-blind, randomized, parallel groups prospective phase II-...
    Medical condition: Women with urgency-frequency syndrome with urinary incontinence due to detrusor instability diagnosed by cystometry. oder Patients with overactive bladder with or without urinary urge incontinenc...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10059617 Overactive bladder LLT
    12.0 10012548 Detrusor instability LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 13:35:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA